OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel cancer therapeutics, announced that David Chaplin, Ph.D., president and chief executive officer, will provide a corporate overview at the 17th Annual BIO CEO & Investor conference on February 10, 2015. The presentation will take place at 10:30 a.m. ET at the Waldorf Astoria Hotel in New York City… Read more »

Shares of Oxigene opened today at $1.56 and are currently trading up at $1.59. OXGN has a 1-year high of $5.40 and a 1-year low of $1.48. The stock’s 50-day moving average is $1.66 and it’s 200-day moving average is $2.05.

On the ratings front, Oxigene (NASDAQ: OXGN has been the subject of a number of recent research reports. In a report issued on November 14, MLV & Co. analyst George Zavoico maintained a Buy rating on OXGN, with a price target of $6.50, which represents a potential upside of 316.7% from where the stock is currently trading. Separately, on November 11, H.C. Wainwright’s Reni Benjamin reiterated a Buy rating on the stock and has a price target of $6.

OxiGene, Inc., is a biopharmaceutical company. It is engaged in development of vascular disrupting agents (VDAs) for the treatment of cancer.